30.10.2017 • NewsAldo BelloniDede WillamsLincare

Path to Linde-Praxair Merger Still Rocky

(c) Linde
(c) Linde

The rocky road to completion of the merger between Germany’s Linde and Praxair of the US just got a little rockier, it appears, but executives of the two industrial gases giants have a chance to smooth it again at a top-level meeting on Nov. 6. Chief topic of discussion will be remarks made by Praxair’s chief financial officer, Matt White, in a private meeting with investors.

After Linde on Oct. 23 lowered its shareholders’ minimum tender requirement from 75% by Oct. 24 to 60%, acceptance of the deal shot up to 68% up to Oct. 27. Analysts then forecast that, even if tenders could later be withdrawn, virtually nothing stood in the way of wrapping up the transaction in the second half of 2018.

At the end of last week, however, White further dampened the already sagging enthusiasm for the business combination on the European side of the Atlantic. At the investors gathering, the executive hinted that some Linde businesses could be put up for sale post-merger.

Up for grabs, White said, could be at least part of Linde’s medical gases portfolio, trading in the US under the Lincare label, as well as its traditional engineering and plant construction business, based in Munich.

The idea that Linde businesses could be dismantled does not sit well with either shareholders or the workforce. The former group, led by investors’ association DSW, have  felt that the tender price is too low. Employee representatives – who earlier sought to torpedo the merger – have long been skeptical that they will get a fair shake under the future US leadership.

Although the new company will be called Linde and based in Ireland, it will be managed from Praxair’s headquarters in Danbury, Connecticut, and be governed by US labor laws, which are generally weaker than in western Europe.

While Lincare has shown softness in the US, in presenting financial results for the third quarter Linde CEO Aldo Belloni told journalists that the engineering arm (which specializes in large petrochemical facilities and traditionally has had good connections in oil-rich Middle East countries) could hold its own under the changed circumstances.  At the same time, he acknowledged that all of the combined businesses will be subjected to a review.

The transaction is still must be approved by antitrust authorities in several key markets. Linde and Praxair are expected to have to divest activities worth around €2.7 billion in annual sales.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.